沃森生物(300142.SZ)：募投項目“玉溪沃森疫苗產業園三期工程項目”等2個項目延期
格隆匯3月20日丨沃森生物(300142.SZ)公佈，根據項目的實際進度和募集資金使用情況，公司基於謹慎原則擬對兩個項目達到預定可使用狀態的時間進行調整，調整後項目投資總額不變，具體調整情況如下：“玉溪沃森疫苗產業園三期工程項目”調整後預計達到可使用狀態日期為2020年12月31日；“上海澤潤研發費用”調整後預計達到可使用狀態日期為2020年6月30日。
1、玉溪沃森疫苗產業園三期工程項目
該項目主要實施Hib疫苗和系列流腦疫苗原液生產車間的易地新建，實施系列肺炎疫苗的產業化車間的新建，建設動物房、科研質檢樓、發貨中心、疫苗生產標準廠房、綜合樓等配套設施。項目總投資約6.47億元，現已完成投資約6.39億元，完成投資進度的98.71%。
現Hib疫苗和系列流腦疫苗原液生產車間已建設完成，其中Hib疫苗車間、流腦疫苗原液生產車間、23價肺炎疫苗生產車間已通過新版GMP認證，13價肺炎疫苗生產車間已建設完成並已投入生產，動物房、科研質檢樓、綜合樓等配套設施已建設完成，疫苗生產標準廠房、聯合疫苗等產品的生產車間建設正在根據產品的研發進度進行，尚有部分收尾工作。根據相關工作的進度，經公司認真研究，擬將項目達到預定可使用狀態的時間調整為2020年12月31日。
2、上海澤潤研發費用
該項目費用主要用於HPV疫苗(2價)臨牀研究以及HPV疫苗(9價)和重組手足口病疫苗的臨牀前研究。項目投資預算為約1.8億元，截至2019年12月31日募集資金已累計投資11,421.38萬元，完成募集資金投資進度63.33%。截至目前，上海澤潤研發項目中，HPV疫苗(9價)和重組手足口病疫苗均已完成了臨牀前研究獲得了臨牀批件，並已處於I期臨牀研究階段，達到了預定狀態；HPV疫苗(2價)於2020年1月完成Ⅲ期臨牀實驗數據揭盲，但尚未獲得臨牀試驗報告。根據HPV疫苗(2價)臨牀試驗報告相關工作的進展情況，經公司認真研究，擬將項目達到預定可使用狀態的時間調整為2020年6月30日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
